八木 洋

Medicine & Life Sciences

1. Liver Transplantation 100%
2. Liver 86%
3. Living Donors 79%
4. Pancreatic Neoplasms 58%
5. Mesenchymal Stem Cells 41%
6. Hepatectomy 39%
7. Hepatocellular Carcinoma 36%
8. Swine 36%
9. Neoplasms 35%
10. Acute Liver Failure 34%
11. Pancreatectomy 28%
12. Transplants 25%
13. Hepatocytes 25%
14. Transplantation 24%
15. Adenocarcinoma 24%
16. Neoplasm Metastasis 23%
17. Induced Pluripotent Stem Cells 20%
18. Liver Failure 19%
19. Therapeutics 18%
20. Survival 17%
21. Pancreaticoduodenectomy 17%
22. Regenerative Medicine 17%
23. Pancreatic Fistula 17%
24. Tissue Donors 17%
25. Pancreas 16%
26. Gallbladder 15%
27. Pancreatic Ducts 15%
28. Recurrence 15%
29. HMGB1 Protein 14%
30. Tomography 14%
31. Carcinoma 14%
32. Bioengineering 13%
33. Portal Vein 13%
34. Stem Cells 13%
35. Pancreatic Intraductal Neoplasms 13%
36. Reperfusion Injury 12%
37. High Mobility Group Proteins 12%
38. Liver Regeneration 12%
39. Regeneration 12%
40. Lymph Nodes 12%
41. Perfusion 11%
42. Organ Transplantation 11%
43. Cryosurgery 11%
44. Neuroendocrine Tumors 11%
45. Bile 11%
46. Cell- and Tissue-Based Therapy 10%
47. Extracellular Matrix 10%
48. Cell Transplantation 10%
49. olanexidine 10%
50. Pheochromocytoma 9%